ReviewThe impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer
Introduction
There is universal agreement that maximal removal of intraperitoneal disease has a survival benefit for patients with metastatic epithelial ovarian cancer (EOC), which is especially true when no visible disease remains at the completion of the operation [1], [2], [3]. There is also agreement that detection of nodal metastasis is important in patients with disease clinically limited to the pelvis, to determine surgical stage, prognosis and the need for adjuvant therapy [4], [5]. There however is controversy in the role of detection and removal of positive nodes in patients with advanced, metastatic intraperitoneal disease as this does not affect surgical stage and its therapeutic benefit remains unclear [6], [7].
In 2009, the International Federation of Gynecology and Obstetrics (FIGO) [8], revised and included in its staging classification of female genital cancers the prognostic significance of direct retroperitoneal tumor invasion in cervical, endometrial and vulvar cancer. Positive groin nodes were added to the staging of vulvar (stage III) and endometrial (stage IVB) cancers. EOC patients with “positive retroperitoneal or inguinal nodes” were included as stage IIIC [9]. The prognostic role of other metastatic nodal sites or retroperitoneal pelvic invasion in EOC remains unclear.
The objective of this study was to estimate the survival impact of pelvic retroperitoneal invasion and distant nodal metastases, other than that of the pelvic and para-aortic nodal regions in advanced EOC patients. The anatomical landmarks of primary cytoreductive surgery in EOC patients will be discussed.
Section snippets
Materials and methods
Data was collected retrospectively from 116 patients with primary EOC and positive nodes (FIGO stage IIIC: 81 and stage IV: 35), treated at Mayo Clinic between 1996 and 2000. Approval was granted by the Mayo Clinic Institutional Review Board. Abstracted data included patient's age, tumor type and grade, FIGO stage, extent of peritoneal disease before debulking (clinical stage) and size of maximal residual tumor diameter after cytoreductive surgery. All patients received adjuvant postoperative
Results
The median patient's age was 65 years (range 24–87 years). The median number of pelvic and/or aortic nodes removed was 31 (range 1–123) and the median number of metastatic nodes was 5 (range: 1–42). Demographics of the cohort and their survival have been previously reported [7], [11], [12].
Pelvic retroperitoneal invasion was present in 22 patients (18.9%), including ureteral obstruction with or without hydronephrosis (n = 10), proximal parametrial involvement (n = 5), proximal parametrial
Discussion
The radicality of primary surgical management in EOC has a direct effect on survival [13]. A previous report on this same cohort of EOC patients with positive nodes and advanced peritoneal disease >2 cm revealed that the extent of initial peritoneal spread and the radicality of the lymphadenectomy (>40 lymph nodes removed) were important prognostic factors for survival [7], [11], [12]. The present study showed two additional independent prognostic factors for survival, the presence of distant,
Conflict of interest statement
We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no financial support for this work that could have influenced its outcome.
Authorship statement
Guarantor of the integrity of the study: A. Pereira, T. Perez-Medina, L. Ortiz-Quintana.
Study concepts: A. Pereira, T. Perez-Medina.
Study design: A. Pereira, T. Perez-Medina.
Definition of intellectual content: A. Pereira, J.F. Magrina, P.M. Magtibay.
Literature research: A. Pereira, A. Rodriguez-Tapia.
Clinical studies: A. Pereira, J.F. Magrina, P.M. Magtibay.
Data acquisition: A. Pereira, A. Rodriguez-Tapia.
Data analysis: A. Pereira, T. Perez-Medina, F. Perez-Milan.
Statistical analysis: A.
References (28)
- et al.
The effect of diameter of largest residual disease after primary cytoreductive surgery on survival in patients with suboptimal residual epithelial ovarian carcinoma: a Gynecologic Oncology Group Study
Am J Obstet Gynecol
(1994) - et al.
Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival
Gynecol Oncol
(1993 Nov) - et al.
Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study
Gynecol Oncol
(2003 Aug) - et al.
Why cancer staging?
Int J Gynecol Obstet
(2006) - et al.
Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer
Int J Gynaecol Obstet
(2006 Nov) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium
Int J Gynaecol Obstet
(2009 May)- et al.
Pelvic and aortic lymph node metastasis in epithelial ovarian cancer
Gynecol Oncol
(2007 Jun) - et al.
Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer
Gynecol Oncol
(1993) - et al.
Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications
J Am Coll Surg
(2003) - et al.
Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors
Gynecol Oncol
(2007 Jan)
Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer
Gynecol Oncol
Distribution of disease at autopsy in 100 women with ovarian cancer
Hum Pathol
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial
J Natl Cancer Inst
The role of lymphadenectomy in node-positive epithelial ovarian cancer
Int J Gynecol Cancer
Cited by (12)
Survival outcomes of ovarian cancer patients treated with secondary cytoreductive surgery for isolated lymph node recurrence: A systematic review of the literature
2019, International Journal of SurgeryCitation Excerpt :The risk of bias and methodological quality of included single arm studies was based on the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies (using the fields 1a, 3e, 3h and 4a that are applicable to single arm studies) [12]. Five articles were excluded from the present systematic review [13–17] as they did not investigate the outcomes of interest. Specifically, two articles investigated the impact of lymphadenectomy in primary staging of advanced EOC cases [13,16], one article focused in patients with neck lymphatic metastasis [15], another one investigated the impact of bulky lymph node resection and systematic lymphadenectomy in patients with recurrent EOC that also had other sites of involvement [17] and the last one investigated the impact of minimally invasive salvage lymphadenectomy for ILNR in patients with gynecological malignancies (including but not limited to EOC) [14].
The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period
2016, Surgical OncologyCitation Excerpt :complete debulking was defined as a residual volume (RV) equal to zero (RV = 0); incomplete debulking was defined as RV < 0.5 cm, 0.6–1 cm, 1.1–1.5 cm, 1.6–2 cm, and >2 cm. Histopathology data included location of metastases removed, overall number of nodes removed, number of positive nodes resected (because of the prognostic significance) [21,23], and the correlation between patient status and 1–40 vs > 40 lymph nodes removed and 1–10 vs > 10 positive nodes removed. Analysis of variance was performed to simultaneously compare means and medians.
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) predictive score for complete resection in primary cytoreductive surgery
2022, International Journal of Gynecological Cancer